AR095117A1 - TRANSFORMANTE DE LEVADURA RECOMBINANTE Y PROCEDIMIENTO DE PREPARACIÓN DE FRAGMENTOS Fc DE INMUNOGLOBULINA USANDO EL MISMO - Google Patents
TRANSFORMANTE DE LEVADURA RECOMBINANTE Y PROCEDIMIENTO DE PREPARACIÓN DE FRAGMENTOS Fc DE INMUNOGLOBULINA USANDO EL MISMOInfo
- Publication number
- AR095117A1 AR095117A1 ARP140100336A ARP140100336A AR095117A1 AR 095117 A1 AR095117 A1 AR 095117A1 AR P140100336 A ARP140100336 A AR P140100336A AR P140100336 A ARP140100336 A AR P140100336A AR 095117 A1 AR095117 A1 AR 095117A1
- Authority
- AR
- Argentina
- Prior art keywords
- immunoglobulin
- fragment
- transformant
- same
- preparation procedure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/18—Baker's yeast; Brewer's yeast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente se refiere a un transformante preparado mediante la introducción de un vector de expresión que comprende un polinucleótido que codifica un fragmento Fc de inmunoglobulina humana en levadura Pichia sp., a un procedimiento de producción de un fragmento Fc de inmunoglobulina, que comprende cultivar el transformante y recuperar el fragmento Fc de inmunoglobulina del cultivo, y a un fragmento Fc de inmunoglobulina, preparado mediante el procedimiento anterior para su uso como un vehículo farmacológico. El transformante se sugiere como una solución a los problemas asociados al uso de células de E. coli o animales como huéspedes para producir fragmentos Fc de inmunoglobulina útiles como vehículos farmacológicos, de modo que pueda encontrar diversas aplicaciones en la producción eficaz y económica de fármacos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130011471A KR102073748B1 (ko) | 2013-01-31 | 2013-01-31 | 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095117A1 true AR095117A1 (es) | 2015-09-30 |
Family
ID=51262604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100336A AR095117A1 (es) | 2013-01-31 | 2014-01-31 | TRANSFORMANTE DE LEVADURA RECOMBINANTE Y PROCEDIMIENTO DE PREPARACIÓN DE FRAGMENTOS Fc DE INMUNOGLOBULINA USANDO EL MISMO |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9394546B2 (es) |
| EP (1) | EP2951284B1 (es) |
| JP (1) | JP6473696B2 (es) |
| KR (1) | KR102073748B1 (es) |
| CN (1) | CN105073977B (es) |
| AR (1) | AR095117A1 (es) |
| AU (1) | AU2014213134B2 (es) |
| CA (1) | CA2899838C (es) |
| DK (1) | DK2951284T3 (es) |
| ES (1) | ES2865443T3 (es) |
| RU (1) | RU2664862C2 (es) |
| SG (1) | SG11201505800RA (es) |
| TW (1) | TWI628279B (es) |
| WO (1) | WO2014119956A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102073748B1 (ko) * | 2013-01-31 | 2020-02-05 | 한미약품 주식회사 | 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법 |
| KR101895634B1 (ko) * | 2013-05-31 | 2018-09-05 | 한미약품 주식회사 | 변이된 힌지 영역을 포함하는 IgG4 Fc 단편 |
| KR20170037247A (ko) * | 2015-09-25 | 2017-04-04 | 한미약품 주식회사 | 개시 메티오닌 잔기를 포함하는 면역글로불린 Fc 영역의 생산방법 |
| JP7394207B2 (ja) | 2019-07-18 | 2023-12-07 | ハンミ ファーマシューティカル カンパニー リミテッド | 新規な中間体製造による持続型薬物結合体の製造方法 |
| US20220273808A1 (en) * | 2019-07-18 | 2022-09-01 | Hanmi Pharm. Co., Ltd | Novel method of preparing protein conjugate |
| WO2021235915A1 (ko) * | 2020-05-22 | 2021-11-25 | 한미약품 주식회사 | 액상 제제 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8504099D0 (en) | 1985-02-18 | 1985-03-20 | Wellcome Found | Physiologically active substances |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| ATE309376T1 (de) | 1990-06-28 | 2005-11-15 | Hoechst Ag | Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung |
| EP0533006A1 (en) | 1991-09-18 | 1993-03-24 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Chimaeric interleukin 5-receptor/immunoglobulin polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
| JPH11174A (ja) * | 1997-06-13 | 1999-01-06 | Asahi Breweries Ltd | 酵母を用いた抗体Ｆａｂ断片の製造法 |
| CZ300762B6 (cs) | 1998-10-16 | 2009-08-05 | Biogen Idec Ma Inc. | Fúzní proteiny interferonu-beta-1a a jejich použití |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| WO2001003737A1 (en) | 1999-07-13 | 2001-01-18 | Bolder Biotechnology Inc. | Immunoglobulin fusion proteins |
| DE10021731B4 (de) | 2000-05-04 | 2005-12-08 | Aventis Pharma Deutschland Gmbh | Cyclipostine, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung derselben |
| US6797493B2 (en) * | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
| ES2372495T3 (es) | 2003-11-13 | 2012-01-20 | Hanmi Holdings Co., Ltd | Método para la producción en masa de la región constante de inmunoglobulina. |
| KR20050098032A (ko) | 2004-01-19 | 2005-10-11 | 타이완 오아시스 테크놀러지 컴퍼니 리미티드 | 백색광 ｌｅｄ 및 상기 백색광 ｌｅｄ로부터 발생된 광의색상을 조정하는 방법 |
| KR100594607B1 (ko) | 2004-11-03 | 2006-06-30 | 재단법인서울대학교산학협력재단 | 신규한 경구투여용 재조합 인간 성장호르몬 분비미생물제제 및 그 제조방법 |
| US8652469B2 (en) | 2005-07-28 | 2014-02-18 | Novartis Ag | M-CSF-specific monoclonal antibody and uses thereof |
| MY149128A (en) * | 2005-08-16 | 2013-07-15 | Hanmi Science Co Ltd | A method for the mass production of immunoglobulin fc region deleted initial methionine residues |
| CN1974601A (zh) | 2005-11-28 | 2007-06-06 | 上海新生源医药研究有限公司 | 一种新型Fc融合蛋白及其生产方法 |
| TW200907059A (en) * | 2007-03-30 | 2009-02-16 | Abbott Lab | Recombinant expression vector elements (rEVEs) for enhancing expression of recombinant proteins in host cells |
| WO2008145138A1 (en) * | 2007-05-31 | 2008-12-04 | Genmab A/S | Recombinant fucose modified monovalent half-antibodies obtained by molecular engineering |
| KR100980411B1 (ko) | 2007-10-15 | 2010-09-07 | 서울대학교산학협력단 | 유전자 변형 미생물의 조건적 자살을 이용한 치료 단백질의소장 전달방법 |
| CN101748145A (zh) * | 2008-12-03 | 2010-06-23 | 中国人民解放军军事医学科学院生物工程研究所 | 表达抗体或抗体类似物的重组酵母菌及其构建方法与应用 |
| EP2275442A1 (en) * | 2009-07-06 | 2011-01-19 | Ludwig-Maximilians-Universität München | Detection and vizualization of the cell cycle in living cells |
| KR102073748B1 (ko) * | 2013-01-31 | 2020-02-05 | 한미약품 주식회사 | 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법 |
-
2013
- 2013-01-31 KR KR1020130011471A patent/KR102073748B1/ko active IP Right Grant
-
2014
- 2014-01-29 TW TW103103472A patent/TWI628279B/zh active
- 2014-01-31 AR ARP140100336A patent/AR095117A1/es not_active Application Discontinuation
- 2014-02-03 RU RU2015133452A patent/RU2664862C2/ru active
- 2014-02-03 ES ES14746164T patent/ES2865443T3/es active Active
- 2014-02-03 WO PCT/KR2014/000901 patent/WO2014119956A1/en active Application Filing
- 2014-02-03 CA CA2899838A patent/CA2899838C/en active Active
- 2014-02-03 EP EP14746164.4A patent/EP2951284B1/en active Active
- 2014-02-03 SG SG11201505800RA patent/SG11201505800RA/en unknown
- 2014-02-03 DK DK14746164.4T patent/DK2951284T3/da active
- 2014-02-03 AU AU2014213134A patent/AU2014213134B2/en active Active
- 2014-02-03 CN CN201480006990.8A patent/CN105073977B/zh active Active
- 2014-02-03 US US14/763,722 patent/US9394546B2/en active Active
- 2014-02-03 JP JP2015555915A patent/JP6473696B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2951284A1 (en) | 2015-12-09 |
| US20150361437A1 (en) | 2015-12-17 |
| DK2951284T3 (da) | 2021-04-26 |
| AU2014213134B2 (en) | 2020-01-23 |
| WO2014119956A1 (en) | 2014-08-07 |
| AU2014213134A1 (en) | 2015-08-13 |
| EP2951284B1 (en) | 2021-03-31 |
| CA2899838A1 (en) | 2014-08-07 |
| ES2865443T3 (es) | 2021-10-15 |
| CA2899838C (en) | 2023-03-07 |
| KR102073748B1 (ko) | 2020-02-05 |
| EP2951284A4 (en) | 2016-08-17 |
| CN105073977A (zh) | 2015-11-18 |
| TWI628279B (zh) | 2018-07-01 |
| KR20140098607A (ko) | 2014-08-08 |
| NZ710448A (en) | 2021-01-29 |
| SG11201505800RA (en) | 2015-08-28 |
| CN105073977B (zh) | 2020-11-10 |
| US9394546B2 (en) | 2016-07-19 |
| JP6473696B2 (ja) | 2019-02-20 |
| JP2016505277A (ja) | 2016-02-25 |
| TW201443234A (zh) | 2014-11-16 |
| BR112015018288A2 (pt) | 2018-08-14 |
| RU2664862C2 (ru) | 2018-08-23 |
| RU2015133452A (ru) | 2017-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR095117A1 (es) | TRANSFORMANTE DE LEVADURA RECOMBINANTE Y PROCEDIMIENTO DE PREPARACIÓN DE FRAGMENTOS Fc DE INMUNOGLOBULINA USANDO EL MISMO | |
| AR103161A1 (es) | Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso | |
| DOP2017000046A (es) | Anticuerpos anti tigit | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| BR112016012129A8 (pt) | métodos para produção, expansão e purificação de células epiteliais do pigmento da retina, composição farmacêutica e uso das células | |
| CR20160333A (es) | Proteinas de fusión de interleucina-2 y usos de las mismas | |
| GT201400162A (es) | Composición y método para el diagnóstico y el tratamiento de las enfermedades asociadas a la degeneración de las neuritas | |
| BR112019000718A2 (pt) | processo para a produção de geopolímero ou compósito de geopolímero | |
| PE20151410A1 (es) | Moleculas biespecificas de union a antigeno activadoras de celulas t | |
| GT201400279A (es) | Jeringa | |
| PE20150752A1 (es) | Proteinas de fusion de interleuquina-2 y usos de las mismas | |
| WO2015032906A3 (en) | Cd70-binding peptides and method, process and use relating thereto | |
| MX2015016835A (es) | Metodo para reticular acido hialuronico; metodo para preparar un hidrogel inyectable; el hidrogel obtenido; el uso del hidrogel obtenido. | |
| CL2016001592A1 (es) | Anticuerpos y métodos de uso | |
| AR088252A1 (es) | Produccion de una proteina de interes mediante un promotor regulable de pichia pastoris | |
| MX359854B (es) | Anticuerpos anti-cxcr3. | |
| BR112014029252B8 (pt) | Método para a construção de uma célula hospedeira fúngica recombinante, célula hospedeira fúngica recombinante, e, método de produção de um polipeptídeo de interesse | |
| ECSP14013132A (es) | Anticuerpos anti-psgl-1 y usos de los mismos | |
| BR112017008672A2 (pt) | anticorpos de il-6 melhorados | |
| NZ707777A (en) | Mdr e. coli specific antibody | |
| BR112017001550A2 (pt) | enxerto de tecido | |
| EA201691754A1 (ru) | Рекомбинантный микроорганизм, экспрессирующий аналог авермектина, и его применение | |
| AR095348A1 (es) | Medios de cultivo celular y métodos de producción de anticuerpos | |
| AR110087A1 (es) | Método para la preparación de células de levadura electrocompetentes, y método para la utilización de dichas células | |
| CR20150585A (es) | Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |